证券代码：300583 证券简称：赛托生物 公告编号：2025-043 山东赛托生物科技股份有限公司董事会决议公告 山东赛托生物科技股份有限公司（以下简称"公司"或"赛托生物"）第四 届董事会第十一次会议于2025年12月4日上午10:00在公司会议室以现场结合通讯 方式召开。本次会议于2025年12月1日以专人送达、电子邮件的方式向所有董事、 高级管理人员送达了会议通知及文件。本次会议应参会董事7人，实际亲自参会董 事7人。公司全体高级管理人员列席了本次会议。会议的召开符合《中华人民共和 国公司法》和《公司章程》的规定。 本次会议由董事长米奇先生主持，全体董事经认真审议并表决，会议审议通 过了以下议案： 1、审议通过《关于变更部分募集资金投资项目的议案》 在综合考虑国家政策、市场环境及公司发展战略等因素的情况下，公司 2022 年向特定对象发行股票募集资金投资项目"高端制剂产业化项目"继续推进软膏 剂生产线及配套公用工程项目建设，新增鼻喷雾剂生产线建设。"高端制剂产业化 项目"总投资变更为 22,937.66 万元，使用募集资金投入金额变更为 13,029.22 万元。同时，变更部分募集资金投入到新项目"生 ...

Group 1 - The company, Saito Bio (300583.SZ), announced adjustments to its fundraising investment plans to enhance the efficiency of fund utilization, with a total investment amount revised to 229.3766 million yuan and the amount of raised funds adjusted to 130.2922 million yuan [1] - The company plans to redirect part of the raised funds to a new project, "Biological Synthesis Technology R&D and Industrialization Project," which will be implemented by its wholly-owned subsidiary, Shandong Jinweiduo Pharmaceutical Co., Ltd. (referred to as "Jinweiduo") [1] - The new project involves an overall investment of 237.1312 million yuan, with an intended raised fund input of 124.3688 million yuan (including interest of 2.7386 million yuan) [1] Group 2 - The company intends to increase its capital in Jinweiduo by 100 million yuan using the raised funds and provide a loan of 24.3688 million yuan to Jinweiduo, with the remaining funds to be sourced by Jinweiduo itself [1]

Group 1 - The company, Saito Bio (300583.SZ), announced adjustments to its fundraising investment plans to improve the efficiency of fund usage, with total investment adjusted to 229.3766 million yuan and the amount of raised funds adjusted to 130.2922 million yuan [1] - Part of the raised funds will be redirected to a new project, "Biological Synthesis Technology R&D and Industrialization Project," led by its wholly-owned subsidiary, Shandong Jinweiduo Pharmaceutical Co., Ltd. (referred to as "Jinweiduo") [1] - The new project involves an overall investment of 237.1312 million yuan, with 124.3688 million yuan of raised funds planned for investment, including interest of 2.7386 million yuan [1] Group 2 - The company plans to increase its investment in Jinweiduo by 100 million yuan using the raised funds and provide a loan of 24.3688 million yuan to Jinweiduo, with the remaining funds to be self-raised by Jinweiduo [1]

变更部分募集资金投资项目的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为山东赛托 生物科技股份有限公司（以下简称"赛托生物"或"公司"）2022 年度以简易程序 向特定对象发行股票并在创业板上市的保荐机构，根据《上市公司募集资金监管规则》 《深圳证券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务（2025 年修订）》和《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》等相关法律、 法规和规范性文件的要求，对赛托生物变更部分募集资金投资项目事项进行了核查， 具体核查情况如下： 一、变更部分募集资金投资项目概述 经中国证券监督管理委员会《关于同意山东赛托生物科技股份有限公司向特定对 象发行股票注册的批复》（证监许可〔2023〕651 号）同意，公司 2022 年度以简易 程序向特定对象发行股票 11,641,762 股，发行价格为 22.47 元/股，募集资金总额为 26,159.04 万元，扣除与本次向特定对象发行股票相关的发行费用 966.80 万元，募集 资金净额为 25,1 ...

山东赛托生物科技股份有限公司 董事、高级管理人员薪酬管理制度 （2025 年 12 月） 第一章 总则 第三条 公司董事、高级管理人员的薪酬方案由公司董事会薪酬与考核委员 会根据董事、高级管理人员的职权范围、在公司生产经营中的作用、工作年限、 当地同类企业薪酬水平等因素进行制定。 第四条 董事薪酬方案报公司董事会、股东会审议通过后实施；高级管理人 员薪酬方案报公司董事会审议通过后实施。 第三章 薪酬标准及发放 第一条 为进一步建立和完善山东赛托生物科技股份有限公司（以下简称" 公司"）董事、高级管理人员的薪酬体系，充分调动公司董事、高级管理人员的 工作积极性，提高公司的经营管理效益，根据《中华人民共和国公司法》《中华 人民共和国证券法》《深圳证券交易所创业板股票上市规则》等法律、行政法规、 规范性文件和《山东赛托生物科技股份有限公司章程》（以下简称"《公司章程》" ）的规定，制定本制度。 第二条 本制度适用于下列人员： （一）董事，包括非独立董事、独立董事； （二）高级管理人员，包括总经理、副总经理、财务总监、董事会秘书及《公 司章程》规定的其他高级管理人员。 第二章 薪酬管理机构 第五条 公司董事薪酬标准： ...

Policy Developments - Jiangxi Province is promoting the development of brain-computer interface medical devices, emphasizing the need for regulatory compliance and collaboration among industry players to seize opportunities in emerging technologies [1] - The market for brain-computer interface medical devices is noted to have significant potential, with a strong development momentum in Jiangxi Province [1] Medical Device Approvals - In October, the National Medical Products Administration approved 204 medical device products, including 173 domestic Class III devices, 10 imported Class III devices, and 21 imported Class II devices [2] Pharmaceutical Logistics - The Shanghai Municipal Drug Administration encourages the development of modern pharmaceutical logistics, advocating for improved storage and management systems to enhance operational efficiency and reduce costs [3] Drug Approvals - Fangsheng Pharmaceutical announced that its Indobufen tablets received a drug registration certificate from the National Medical Products Administration, allowing for production [4] - Saito Bio's application for the chemical raw material drug Mometasone Furoate has been approved, indicating its use in treating asthma and skin conditions [5] - Tianyao Pharmaceutical received a drug registration certificate for Metoclopramide injection, which is used for treating nausea and vomiting [6] Capital Market Activities - Yingsi Intelligent submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for its AI-driven drug development initiatives [7][8] - Rejuve Bio plans to repurchase shares worth between 100 million and 200 million yuan to support employee stock ownership plans [9] Industry Developments - AstraZeneca's Baxdrostat demonstrated significant reductions in 24-hour average systolic blood pressure in treatment-resistant hypertension patients during the Bax24 Phase III trial, achieving a reduction of 14.0 mmHg compared to placebo [10][11] - The drug showed good overall tolerability and consistent safety profiles, with a notable percentage of patients achieving target blood pressure levels [11] - Maiwei Bio's IL-11 monoclonal antibody 9MW3811 received approval for Phase II clinical trials targeting pathological scars, marking it as the first IL-11 targeted drug to enter clinical trials for this indication [12] - Aiwei Technology's subsidiary obtained a medical institution practice license, enabling it to provide third-party medical testing services [13] - Anke Bio signed an exclusive agency framework agreement with Boshengji for the PA3-17 injection product, aimed at enhancing its product portfolio in the innovative drug market [14][15]

Core Viewpoint - Saito Biopharmaceuticals (300583) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Mometasone Furoate, a potent anti-inflammatory drug [1] Group 1: Product Approval - The approval notification allows for the use of Mometasone Furoate in inhalation and topical formulations [1] - As an inhalation agent, it can be combined with β2-adrenergic agonists and/or long-acting acetylcholine receptor antagonists, primarily for asthma treatment [1] - For topical use, it is indicated for conditions such as eczema, neurodermatitis, atopic dermatitis, and pruritus [1]

Core Viewpoint - Saito Bio (300583.SZ) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Mometasone Furoate, which has strong anti-inflammatory properties and is used in inhalers and topical skin medications [1] Group 1: Product Approval - The approval pertains to Mometasone Furoate, which can be used as an inhalant in combination with β2-adrenergic agonists and/or long-acting acetylcholine receptor antagonists, primarily for asthma treatment [1] - As a topical medication, Mometasone Furoate is indicated for conditions such as eczema, neurodermatitis, atopic dermatitis, and skin pruritus [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received approval for the listing application of Mometasone Furoate, a chemical raw material drug, from the National Medical Products Administration, enhancing the company's product line and market competitiveness in the chemical raw material drug sector [1] Group 1 - The approval of Mometasone Furoate signifies that the raw material drug meets national drug review technical standards [1] - Mometasone Furoate is known for its potent anti-inflammatory properties and is used in inhalants and topical medications for treating asthma, eczema, neurodermatitis, atopic dermatitis, and skin itching [1] - This approval will further enrich the company's product offerings, contributing positively to its competitive position in the chemical raw material drug market [1]

Core Viewpoint - The company Saito Bio (300583.SZ) announced that its subsidiary Shandong Sry Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Mometasone Furoate [1] Group 1: Product Information - Mometasone Furoate is known for its strong anti-inflammatory properties and can be used in inhalers and topical skin medications [1] - When used as an inhaler, it can be combined with β2-adrenergic agonists and/or long-acting acetylcholine receptor antagonists, primarily for the treatment of asthma [1] - As a topical medication, it is effective in treating eczema, neurodermatitis, atopic dermatitis, and skin itching [1]